NKTX

Nkarta is a clinical-stage, pre-commercial biopharma with zero product revenue and a five-year run of nine-figure losses (net loss -$104M in FY2025, accumulated deficit -$648.3M). There is nothing to value on an earnings or sales basis: ROE is -33.3%, operating cash flow was -$88.7M, and the entire equity case rests on the single Phase 1 asset NKX019, an off-the-shelf CD19 CAR-NK cell therapy now repositioned from oncology toward autoimmune disease (lupus nephritis, scleroderma, myositis, vasculitis). Per the rubric this is textbook 'unknowable risk' — value hinges on binary clinical readouts, not on the income statement.

What keeps this a hold rather than an avoid is the balance sheet and the price. At $3.22 on 71.3M shares the market cap is ~$230M, against $312M of stockholders' equity and $283M of current assets versus only $91.9M of total liabilities (liabilities/equity just 0.29x) — the stock trades below book and roughly at net-of-all-liabilities current assets, giving a genuine downside cushion unusual for a Phase 1 name. The March 2025 workforce reduction and pipeline reprioritization cut R&D 6.5% and shrank operating cash burn 11%; against ~$283M of current assets that implies roughly three years of runway before dilution becomes urgent, so there is no imminent financing gun to the head.